Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
Vitamin C also serves as a potent antioxidant, neutralizing free radicals that can damage the skin and accelerate aging
It can also help manage obstructive sleep apnea
Not everyone is a candidate for GLP-1 therapy, and risks and benefits are reviewed before starting.
If you're a man over 30, low testosterone might be working against you